Technology adoption fuels growth for pharma tech firm
Company has experienced double digit growth across its automation, MES and managed services offering.
Zenith Technologies has strengthened its global workforce, recruiting 100 people over the past year in response to growing demand for manufacturing execution system (MES) and automation technology in the pharma sector.
The global life science technology firm, with headquarters in Cork and 16 offices worldwide, has experienced double digit growth across its automation, MES and managed services offering, which has been supported by around a 50% increase in headcount since 2014. It’s 700 plus strong team of engineers supports some of the world’s largest pharma firms with the implementation of new technology.
As demand for technology grows in the pharma sector against a backdrop of an industry-wide engineering skills shortage, Zenith is also investing in training future talent. The company has just made a record intake of more than 30 graduates from across Ireland, the UK, the US and Singapore.
Shea Fahy, HR director at Zenith commented: “Recruiting skilled and experienced staff is important for the future of our business and the growing adoption of technology in the life sciences space also demands engineers to ensure effective implementation and support solutions. We’re proud that our one-year graduate programme addresses the engineering skills gap head on, supporting the talent of the future.”
Graduates will benefit from an initial 2-week induction and 6-week mentoring session from experienced engineers, where they will learn to identify customer challenges and select the appropriate technological solutions.
“We have worked hard to build up a reputation as a trusted technology partner in the life sciences sector. Our employees have the opportunity to work with some of the largest pharmaceutical companies in the world, with a structured approach to continued learning and development to enhance their engineering skillset.
“We are incredibly proud of the growth we have been able to achieve. We will continue to strengthen our ability to support our customers and by the end of this year, we expect to have doubled our headcount from 2014,” Fahy continued.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.